Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$0.87 - $1.71 $501 - $984
576 Added 159.12%
938 $1,000
Q2 2023

Aug 15, 2023

SELL
$0.83 - $1.18 $6,761 - $9,612
-8,146 Reduced 95.75%
362 $0
Q1 2023

May 12, 2023

BUY
$0.8 - $4.98 $6,806 - $42,369
8,508 New
8,508 $6,000
Q3 2022

Nov 14, 2022

SELL
$2.5 - $37.95 $7,032 - $106,753
-2,813 Reduced 95.1%
145 $0
Q2 2022

Aug 12, 2022

SELL
$1.75 - $11.34 $19 - $124
-11 Reduced 0.37%
2,958 $7,000
Q1 2022

May 16, 2022

SELL
$10.21 - $20.29 $134,047 - $266,387
-13,129 Reduced 81.56%
2,969 $31,000
Q4 2021

Feb 14, 2022

BUY
$16.76 - $22.99 $244,193 - $334,964
14,570 Added 953.53%
16,098 $318,000
Q3 2021

Nov 15, 2021

BUY
$13.15 - $22.56 $17,660 - $30,298
1,343 Added 725.95%
1,528 $28,000
Q2 2021

Aug 16, 2021

SELL
$18.28 - $33.05 $29,851 - $53,970
-1,633 Reduced 89.82%
185 $3,000
Q1 2021

May 13, 2021

SELL
$29.34 - $60.2 $114,572 - $235,081
-3,905 Reduced 68.23%
1,818 $59,000
Q4 2020

Feb 09, 2021

BUY
$27.25 - $55.82 $155,951 - $319,457
5,723 New
5,723 $315,000

Others Institutions Holding PRAX

# of Institutions
1
Shares Held
75K
Call Options Held
0
Put Options Held
0

About Praxis Precision Medicines, Inc.


  • Ticker PRAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,576,100
  • Market Cap $3.26B
  • Description
  • Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...
More about PRAX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.